[go: up one dir, main page]

UY38979A - Tetrahidrofuranos sustituidos como moduladores de canales de sodio - Google Patents

Tetrahidrofuranos sustituidos como moduladores de canales de sodio

Info

Publication number
UY38979A
UY38979A UY0001038979A UY38979A UY38979A UY 38979 A UY38979 A UY 38979A UY 0001038979 A UY0001038979 A UY 0001038979A UY 38979 A UY38979 A UY 38979A UY 38979 A UY38979 A UY 38979A
Authority
UY
Uruguay
Prior art keywords
sodium channel
tetrahydrofurans
replaced
channel modulators
compounds
Prior art date
Application number
UY0001038979A
Other languages
English (en)
Inventor
John Durrant Steven
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of UY38979A publication Critical patent/UY38979A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Amplitude Modulation (AREA)
  • Amplifiers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos y sus sales farmacéuticamente aceptables, de utilidad como inhibidores de canales de sodio. También se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos de uso de los compuestos, sales farmacéuticamente aceptables, y composiciones farmacéuticas en el tratamiento de varios trastornos, incluido el dolor.
UY0001038979A 2019-12-06 2020-12-04 Tetrahidrofuranos sustituidos como moduladores de canales de sodio UY38979A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962944869P 2019-12-06 2019-12-06

Publications (1)

Publication Number Publication Date
UY38979A true UY38979A (es) 2021-07-30

Family

ID=73854989

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038979A UY38979A (es) 2019-12-06 2020-12-04 Tetrahidrofuranos sustituidos como moduladores de canales de sodio

Country Status (29)

Country Link
US (3) US11834441B2 (es)
EP (2) EP4506001A2 (es)
JP (1) JP2023504546A (es)
KR (1) KR20220124176A (es)
CN (1) CN114945566B (es)
AR (1) AR120680A1 (es)
AU (1) AU2020397059A1 (es)
BR (1) BR112022010924A2 (es)
CA (1) CA3164134A1 (es)
CL (1) CL2022001489A1 (es)
CO (1) CO2022008969A2 (es)
CR (1) CR20220316A (es)
DK (1) DK4069691T3 (es)
DO (1) DOP2022000115A (es)
EC (1) ECSP22052564A (es)
FI (1) FI4069691T3 (es)
HR (1) HRP20241695T1 (es)
IL (1) IL293592A (es)
JO (1) JOP20220130A1 (es)
MX (1) MX2022006865A (es)
PE (1) PE20230300A1 (es)
PH (1) PH12022551379A1 (es)
PL (1) PL4069691T3 (es)
PT (1) PT4069691T (es)
RS (1) RS66307B1 (es)
SM (1) SMT202400488T1 (es)
TW (1) TW202128675A (es)
UY (1) UY38979A (es)
WO (1) WO2021113627A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021024224A2 (pt) 2019-05-31 2022-04-26 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
PH12021553233A1 (en) 2019-07-16 2022-09-19 Univ Michigan Regents Imidazopyrimidines as eed inhibitors and the use thereof
UY38979A (es) 2019-12-06 2021-07-30 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
IL308934A (en) * 2021-06-04 2024-01-01 Vertex Pharma Manufacturing process of converted natran tetrahydrofuran channel modulators
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
KR20240031300A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
TW202317520A (zh) 2021-06-15 2023-05-01 德商歌林達有限公司 經取代之吡唑醯胺
IL316433A (en) 2022-04-25 2024-12-01 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain
WO2024041613A1 (zh) * 2022-08-24 2024-02-29 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2024046253A1 (zh) * 2022-08-28 2024-03-07 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
WO2024046409A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2024123815A1 (en) * 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
US20240252473A1 (en) 2022-12-14 2024-08-01 Gruenenthal Gmbh Sulfoximines as inhibitors of NaV1.8
EP4385979A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Multicyclic inhibitors of nav1.8
EP4385980A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Indazoles as inhibitors of nav1.8
EP4385984A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Pyridine-n-oxides as inhibitors of nav1.8
TW202440561A (zh) * 2023-01-06 2024-10-16 大陸商西藏海思科製藥有限公司 四氫噻吩衍生物及其在醫藥上的應用
WO2024188367A1 (zh) * 2023-03-10 2024-09-19 西藏海思科制药有限公司 一种四氢呋喃衍生物及其在医药上的应用
CN118812519A (zh) * 2023-04-19 2024-10-22 武汉人福创新药物研发中心有限公司 取代的四氢呋喃作为Nav1.8抑制剂
WO2024217528A1 (zh) * 2023-04-20 2024-10-24 西藏海思科制药有限公司 一种杂环化合物及其在医药上的应用
CN119371405A (zh) * 2023-07-26 2025-01-28 上海闻耐医药科技有限公司 多取代吡咯烷类衍生物、其制备方法及用途
CN119143737A (zh) * 2024-11-18 2024-12-17 嘉兴安帝康生物科技有限公司 四氢呋喃甲酰胺类钠通道调节剂及其在医药上的应用

Family Cites Families (412)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844732A (en) 1985-10-24 1989-07-04 Daicel Chemical Industries Ltd. Pyridine-3-carboxamide derivatives
JPH075554B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ５−ブロモピリドン−３−カルボキサミド化合物の製法
JPH075555B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ピリドン−３−カルボキサミドの製法
EP0407217A1 (en) 1989-07-07 1991-01-09 Schering Corporation Pharmaceutically active compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
JPH05107574A (ja) 1991-03-12 1993-04-30 Mitsui Petrochem Ind Ltd 有機非線形光学材料
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
IT1254134B (it) 1992-01-16 1995-09-08 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso chimicamente modificati.
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
SG65570A1 (en) 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
US5559127A (en) 1992-10-14 1996-09-24 Merck & Co., Inc. Fibrinogen receptor antagonists
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB2300856A (en) 1995-05-16 1996-11-20 Pfizer Ltd Beta-lactam preparation
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
BR9712527A (pt) 1996-10-16 2000-03-08 Icn Pharmaceuticals L-nucleosìdeos monocìclicos, análogos e seus empregos
WO1998018466A2 (en) 1996-10-31 1998-05-07 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
US5942508A (en) 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
CA2307613A1 (en) 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
AU1230100A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
BR0010126A (pt) 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
IL155155A0 (en) 1999-09-17 2003-10-31 Cor Therapeutics Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
EP1216231A2 (en) 1999-09-17 2002-06-26 Millennium Pharmaceuticals, Inc. INHIBITORS OF FACTOR Xa
EA200200292A1 (ru) 1999-10-29 2002-10-31 Пфайзер Продактс Инк. Производные гигромицина
MXPA02004442A (es) 1999-11-05 2002-09-02 Scient S C R A S Soc Francesa Nuevos compuestos heterociclicos y su uso como medicamentos.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
JP2004500389A (ja) 2000-03-09 2004-01-08 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒメディエーターの治療での使用
AU2001275881B2 (en) 2000-07-10 2006-04-06 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
JP2004508359A (ja) 2000-09-06 2004-03-18 ニューロゲン　コーポレイション アリール置換テトラヒドロインダゾール、及び、ｇａｂａ−ａ受容体に対するリガンドとしてのそれらの使用
AU2002255473A1 (en) 2000-10-24 2002-09-04 Glaxo Group Limited Process for preparing intermediates of hiv protease inhibitors
EP1330432A2 (en) 2000-11-04 2003-07-30 Aventis Pharma Limited Substituted alkanoic acids
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
NZ526697A (en) 2001-01-16 2005-05-27 Astrazeneca Ab Therapeutic heterocyclic compounds
CN100352808C (zh) 2001-03-05 2007-12-05 杜邦公司 杂环二酰胺无脊椎害虫控制剂
WO2002083628A1 (en) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003070912A2 (en) 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
HU228195B1 (hu) 2001-09-21 2013-01-28 Bristol Myers Squibb Co Pirazolo-piridin gyûrût tartalmazó laktámok és származékaik, valamint az ezeket tartalmazó Xa faktor gátlására szolgáló gyógyszerkészítmények
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
AU2002344567A1 (en) 2001-11-28 2003-06-10 Daiso Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
CN1620449A (zh) 2002-01-22 2005-05-25 纳幕尔杜邦公司 二酰胺化合物无脊椎害虫防治剂
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
PT1490064E (pt) 2002-02-14 2009-12-28 Pharmacia Corp Piridinonas substituídas como moduladores de p38 map-quinase
JP2005523292A (ja) 2002-02-21 2005-08-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体モジュレーター
CA2477741A1 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
US7622592B2 (en) 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
EP1618087B1 (en) 2003-01-08 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Antibacterial agents
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
CA2521130C (en) 2003-04-01 2013-05-14 Activx Biosciences, Inc. Acyl-phosphate and phosphonate probes and methods of their synthesis and use in proteomic analysis
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CA2528438A1 (en) 2003-06-03 2005-01-06 Novartis Ag P-38 inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US8202861B2 (en) 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
EP1664071A1 (en) 2003-08-21 2006-06-07 Griffith University Novel sulfenamide oxides
JP2007502779A (ja) 2003-08-21 2007-02-15 グリフィス ユニバーシティ 新規スルフェンアミド
US7713941B2 (en) 2003-08-27 2010-05-11 Biota Scientific Management Pty Ltd Tricyclic nucleosides or nucleotides as therapeutic agents
WO2005033079A1 (ja) 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP4526801B2 (ja) 2003-11-13 2010-08-18 新日鐵化学株式会社 複素環化合物の製造方法
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
MXPA06005882A (es) 2003-11-25 2006-06-27 Pfizer Prod Inc Metodo de tratamiento de la aterosclerosis.
EP1802580A2 (en) 2004-07-23 2007-07-04 Pfizer, Inc. Pyridine derivatives
CA2577169A1 (en) 2004-08-16 2006-02-23 The University Of Queensland Metabolism-modulating agents and uses therefor
CN101068794B (zh) 2004-09-02 2012-12-19 沃泰克斯药物股份有限公司 可用作离子通道调控剂的喹唑啉
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
US8461128B2 (en) 2005-04-15 2013-06-11 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
NZ563478A (en) 2005-05-09 2011-04-29 Vertex Pharma Processes for preparing ureido-benzylcarbamate derivatives
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US7683066B2 (en) 2005-05-20 2010-03-23 Vertex Pharmaceuticals Incorporated Isoquinolines useful as modulators of ion channels
WO2006130493A2 (en) 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
EA200801128A1 (ru) 2005-10-21 2008-10-30 Глэксо Груп Лимитед Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US20070203224A1 (en) 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
CA2642754A1 (en) 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US7480400B2 (en) 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
CA2648202A1 (en) 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
WO2008001195A2 (en) 2006-06-27 2008-01-03 Glenmark Pharmaceuticals S.A. Novel processes for the preparation of dpp iv inhibitors
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
KR101555258B1 (ko) 2006-08-08 2015-09-24 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물
WO2008018129A1 (fr) 2006-08-09 2008-02-14 Shinichiro Isobe Procédé de détection de protéine et colorant fluorescent utilisé à cet effet
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CN101534831B (zh) 2006-09-11 2013-07-17 柯瑞斯公司 包含锌结合基团的取代的酪氨酸抑制剂
ATE545416T1 (de) 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc Verwendung von spiro-oxindol-verbindungen als therapeutika
BRPI0719345A2 (pt) 2006-11-27 2014-03-18 Novartis Ag Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
EP2101760B1 (en) 2006-12-08 2013-02-27 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US20080234332A1 (en) 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2010531304A (ja) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー
JP5492770B2 (ja) 2007-06-26 2014-05-14 サノフイ ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成
CN101711245B (zh) 2007-07-19 2015-03-25 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
CA2700088A1 (en) 2007-09-26 2009-04-02 Astellas Pharma Inc. Quinolone derivative
JP5580201B2 (ja) 2007-10-08 2014-08-27 アドビヌス・セラピューティクス・プライベート・リミテッド グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用
JP5436434B2 (ja) 2007-10-11 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアミド
MX2010003865A (es) 2007-10-11 2010-06-01 Vertex Pharma Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2009069132A2 (en) 2007-11-29 2009-06-04 Ramot At Tel Aviv University Ltd. Novel reverse transcriptase inhibitors
CA2709301C (en) 2007-12-13 2016-05-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110046199A1 (en) 2008-01-17 2011-02-24 Purdue Research Foundation Small molecule inhibitors of hiv proteases
US20120108630A1 (en) 2008-02-12 2012-05-03 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog Pathway Antagonists and Methods of Use
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
PL2959900T3 (pl) 2008-06-16 2017-11-30 University Of Tennessee Research Foundation Związek do leczenia raka
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8846947B2 (en) 2008-07-03 2014-09-30 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
CN102439025B (zh) 2008-09-06 2017-08-01 坎姆根公司 Rna合成－用于反向合成rna的亚磷酰胺，以及在3’‑末端合成rna的配体、发色团和修饰物的方便引入中的应用
US8541569B2 (en) 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
WO2010031713A1 (en) 2008-09-18 2010-03-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN102227420B (zh) 2008-09-29 2015-06-24 西特里斯药业公司 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2184273A1 (de) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
CA2743241A1 (en) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
EP2376473A4 (en) 2008-12-10 2012-05-02 Merck Canada Inc 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
KR101370185B1 (ko) 2008-12-23 2014-03-05 에프. 호프만-라 로슈 아게 Ｐ２ｘ7 조절제로서의 디히드로피리돈 아미드
WO2010074193A1 (ja) 2008-12-26 2010-07-01 大日本住友製薬株式会社 新規２環性複素環化合物
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
TWI770731B (zh) 2009-04-28 2022-07-11 美商環球展覽公司 具有甲基-d3取代之銥錯合物
US9174999B2 (en) 2009-05-07 2015-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
WO2010138576A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
ES2453097T3 (es) 2009-05-27 2014-04-04 Abbvie Inc. Inhibidores de pirimidina de actividad quinasa
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
EP2477625A4 (en) 2009-09-14 2012-10-24 Phusis Therapeutics Inc PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
WO2011037731A1 (en) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
HUE028983T2 (en) 2010-05-06 2017-01-30 Vertex Pharma Heterocyclic chromene-spirocyclic piperidine amides as ion channel modulators
US20130116284A1 (en) 2010-05-10 2013-05-09 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
WO2012007836A1 (en) * 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012020725A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
CN103442568A (zh) 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
FI20106119A0 (fi) 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus
GB201020076D0 (en) 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
ES2542431T3 (es) 2010-11-29 2015-08-05 Pfizer Inc Monobactamas
CA2820203A1 (en) 2010-12-13 2012-06-21 Neural Pathways, Llc Handheld emg stimulator device with adjustable shaft length
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
WO2012097330A2 (en) 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
JP2012167027A (ja) 2011-02-10 2012-09-06 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有する縮合ヘテロ環誘導体
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
CA2830234A1 (en) 2011-03-15 2012-09-20 Abbvie Inc. Nuclear hormone receptor modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP5866100B2 (ja) 2011-04-13 2016-02-17 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
WO2012170371A1 (en) 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
EP2755965B1 (en) 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
SG11201401032YA (en) 2011-10-26 2014-07-30 Pfizer Ltd (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
NZ627259A (en) 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
FR2985916B1 (fr) 2012-01-25 2015-12-04 Univ Bordeaux Segalen Decontamination par hydrogels d'echantillons aqueux contenant des nanoparticules
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
CA2864091A1 (en) 2012-02-08 2013-08-15 Graffinity Pharmaceuticals Gmbh Ligands for antibody and fc-fusion protein purification by affinity chromatography iv
WO2013124040A1 (en) 2012-02-22 2013-08-29 Merck Patent Gmbh Liquid crystalline medium
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
JP5798066B2 (ja) 2012-03-08 2015-10-21 富士フイルム株式会社 化合物、液晶組成物、高分子材料およびフィルム
JP5804991B2 (ja) 2012-03-19 2015-11-04 富士フイルム株式会社 光反射フィルム、自動車用フロントガラス、建材用ガラス
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
AU2013269798A1 (en) 2012-05-30 2014-10-02 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
JP5867298B2 (ja) 2012-06-06 2016-02-24 Jsr株式会社 フォトレジスト組成物及びレジストパターン形成方法
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2014005125A2 (en) 2012-06-29 2014-01-03 Biotium, Inc. Fluorescent compounds and uses thereof
US9040498B2 (en) 2012-07-06 2015-05-26 Research Foundation Of The City University Of New York 1,2,3-Triazolyl purine derivatives
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
JP6220786B2 (ja) 2012-07-19 2017-10-25 大日本住友製薬株式会社 １−（シクロアルキルカルボニル）プロリン誘導体
US9550798B2 (en) 2012-07-27 2017-01-24 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014020152A1 (en) 2012-08-02 2014-02-06 Graffinity Pharmaceuticals Gmbh Ligands for apheresis and immunoabsorption
US9428511B2 (en) 2012-09-06 2016-08-30 Bristol-Myers Squibb Company Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
AU2013318206B2 (en) 2012-09-20 2018-07-26 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
FR2997851B1 (fr) 2012-11-09 2014-11-28 Oreal Composition comprenant un derive dicarbonyle et procede de lissage des cheveux a partir de cette composition
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
MX2015006192A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
KR20150090917A (ko) 2012-12-06 2015-08-06 머크 샤프 앤드 돔 코포레이션 디술피드-차폐 전구약물 조성물 및 방법
WO2014108407A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
DK2951172T3 (en) 2013-01-29 2017-07-17 Redx Pharma Plc PYRIDINE DERIVATIVES LIKE SOFT ROCK INHIBITORS
AU2014212431B2 (en) 2013-01-31 2018-04-05 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
CN108164457B (zh) 2013-01-31 2021-07-09 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
TWI631105B (zh) 2013-01-31 2018-08-01 維泰克斯製藥公司 作爲鈉通道調節劑之喹啉及喹噁啉醯胺
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015003991A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Novel microbiocides
WO2015003723A1 (en) 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
US20160145304A1 (en) 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
UA119147C2 (uk) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
CA2918534A1 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
US9789096B2 (en) 2013-09-04 2017-10-17 Board Of Regents Of The University Of Texas System Methods and compositions for selective and targeted cancer therapy
ES2927955T3 (es) 2013-09-11 2022-11-14 Univ Emory Composiciones de nucleótidos y nucleósidos y sus usos
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
CA2925862A1 (en) 2013-10-01 2015-04-09 Glaxosmithkline Intellectual Property Development Limited Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
US20160264614A1 (en) 2013-10-02 2016-09-15 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US9700881B2 (en) 2013-10-09 2017-07-11 Emory University Heterocyclic coupling catalysts and methods related thereto
WO2015084796A1 (en) 2013-12-03 2015-06-11 E. I. Du Pont De Nemours And Company Pyrrolidinones as herbicides
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
EP2883934B1 (en) 2013-12-16 2019-11-13 Merck Patent GmbH Liquid-crystalline medium
KR20160106627A (ko) 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CA2944549A1 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
WO2015162244A1 (en) 2014-04-25 2015-10-29 Basf Se N-acylamidine compounds
JP6295992B2 (ja) 2014-05-09 2018-03-20 信越化学工業株式会社 単量体の製造方法
US9701627B2 (en) 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170175129A1 (en) 2014-06-19 2017-06-22 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
WO2016007837A1 (en) 2014-07-11 2016-01-14 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors
AU2015289643B2 (en) 2014-07-16 2020-10-22 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
KR20230026515A (ko) 2014-09-10 2023-02-24 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
JP2016079098A (ja) 2014-10-10 2016-05-16 塩野義製薬株式会社 セフェム化合物
US10865181B2 (en) 2014-11-05 2020-12-15 University Of Kansas Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
JP6899770B2 (ja) 2014-12-10 2021-07-07 マース インコーポレーテッドＭａｒｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 香味組成物およびそれを含有するペットフード製品
FR3030242B1 (fr) 2014-12-18 2018-01-26 L'oreal Emulsion contenant un tensioactif gemine ayant deux groupements amide gras et un filtre uv organique hydrosoluble
CN105985330A (zh) 2015-02-04 2016-10-05 苏州旺山旺水生物医药有限公司 一类杂环化合物、其制备方法和用途
JP6394430B2 (ja) 2015-02-13 2018-09-26 信越化学工業株式会社 化合物、高分子化合物、レジスト材料及びパターン形成方法
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
EP3085360A1 (en) 2015-04-20 2016-10-26 Universite De Bordeaux Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
KR20180004811A (ko) 2015-05-15 2018-01-12 길리애드 사이언시즈, 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서의 활성을 갖는 벤즈이미다졸 및 이미다조피리딘 카르복스이미드아미드 화합물
RU2017142979A (ru) 2015-06-02 2019-07-15 ЭфЭмСи Корпорейшн Замещенные циклические амиды и их применение в качестве гербицидов
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
KR20180025927A (ko) 2015-07-06 2018-03-09 바이엘 크롭사이언스 악티엔게젤샤프트 농약으로서의 질소 함유 헤테로사이클
AU2016291578C1 (en) 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
CN106518767A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途
CN106518766A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 新型二芳基脲类化合物,其制备方法及其医药用途
WO2017051319A1 (en) 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
JP2018534270A (ja) 2015-09-30 2018-11-22 サイトワン セラピューティクス， インコーポレイテッド 疼痛の治療のための１１，１３−修飾サキシトキシン
WO2017059446A1 (en) 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
WO2017062751A1 (en) 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
EP3362461B1 (en) 2015-10-16 2022-03-16 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
EP3381913B1 (en) 2015-11-27 2021-03-31 Mitsubishi Tanabe Pharma Corporation 2-(((pyrrolidin-3-yl)carbonyl)amino)-1h-imidazole derivatives as melanocortin receptor 1 (mcr1) agonists for treating rheumatoid arthritis
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
KR102606339B1 (ko) 2016-03-02 2023-11-24 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
IL261606B (en) 2016-03-16 2022-09-01 Kura Oncology Inc Substituted inhibitors of menin-mll and methods of use
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
CN105906591A (zh) 2016-04-22 2016-08-31 中国药科大学 2-氨基-γ-丁内酯类盐酸盐的合成
TWI763668B (zh) * 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2017223260A1 (en) 2016-06-23 2017-12-28 Albert Einstein College Of Medicine, Inc. Pu.1 inhibitors
CN106220667B (zh) 2016-07-21 2018-10-30 北京航空航天大学 螺环有机硅化合物及其应用
WO2018045106A1 (en) 2016-08-30 2018-03-08 Ohio State Innovation Foundation Anti-fungal treatment
WO2018055235A1 (en) 2016-09-21 2018-03-29 University Of Helsinki Isoxazole-amides for treating cardiac diseases
CA3038331A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
JP7179735B2 (ja) 2016-09-28 2022-11-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 重合性液晶材料および重合された液晶膜
WO2018067636A1 (en) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Compositions and methods for selective carbonylation of heterocyclic compounds
CN110099909B (zh) 2016-12-12 2021-11-19 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
US20190388426A1 (en) 2017-01-30 2019-12-26 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
WO2018163077A1 (en) * 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
EP3601291A1 (en) 2017-03-29 2020-02-05 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183871A1 (en) 2017-03-30 2018-10-04 Shaw Industries Group, Inc. Carpet tiles and systems and methods of making same
US20200113901A1 (en) 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
JP2020100564A (ja) 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
BR112019021899A2 (pt) 2017-04-20 2020-08-18 The Regents Of The University Of California moduladores de k-ras
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
CN107033149B (zh) 2017-06-12 2020-01-03 上海交通大学 一种dpp-4酶抑制剂及其制备和应用
EP3642182A4 (en) 2017-06-21 2020-12-09 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS
EP3651752B1 (en) 2017-07-11 2024-11-20 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN109320509B (zh) 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN109384712B (zh) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
MX2020001793A (es) 2017-08-17 2020-07-22 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
WO2019036562A1 (en) 2017-08-18 2019-02-21 Saint Louis University ERR INVERSE AGONISTS
CN109553608B (zh) 2017-09-26 2020-12-08 北京大学 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途
EA202090955A1 (ru) 2017-10-18 2020-11-27 Эпизайм, Инк. Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2021500326A (ja) 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
WO2019094732A1 (en) 2017-11-10 2019-05-16 Academia Sinica Inhibitors of cyclic-amp response element-binding protein
WO2019097515A1 (en) 2017-11-15 2019-05-23 Metabomed Ltd Acss2 inhibitors and methods of use thereof
KR20190076339A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 신규한 2,6-나프티리딘 2-옥시드 유도체 화합물 및 이의 용도
EP3502684A1 (en) 2017-12-22 2019-06-26 Universite De Bordeaux Method for metal ion detection in aqueous solutions using nucleolipid compounds
WO2019137201A1 (zh) 2018-01-09 2019-07-18 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
SG11202006723SA (en) 2018-02-08 2020-08-28 Enyo Pharma Non-fused thiophene derivatives and their uses
CN111918650A (zh) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 治疗疼痛的方法
US20210153932A1 (en) 2018-04-05 2021-05-27 St. Jude Medical, Cardiology Division, Inc. High density electrode mapping catheter
WO2019206925A1 (en) 2018-04-27 2019-10-31 Merck Patent Gmbh Polymerisable liquid crystal material and polymerised liquid crystal film
KR20210005159A (ko) 2018-04-27 2021-01-13 메르크 파텐트 게엠베하 중합성 액정 물질 및 중합된 액정 필름
WO2019222414A1 (en) 2018-05-16 2019-11-21 Belite Bio, Llc Fatty acid analogues and methods of use
TWI812739B (zh) 2018-06-21 2023-08-21 景凱生物科技股份有限公司 Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用
SG11202100137TA (en) 2018-07-09 2021-02-25 Lieber Institute Inc PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
JP2021530478A (ja) 2018-07-09 2021-11-11 リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物
EP3831823A4 (en) 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
WO2020034062A1 (en) 2018-08-13 2020-02-20 Rhodia Operations Process for the reductive amination of a carbonyl compound
WO2020034058A1 (en) 2018-08-13 2020-02-20 Rhodia Operations PROCESS FOR REDUCTIVE AMINATION OF α,β-UNSATURATED CARBONYL COMPOUND
EP3847159A2 (en) 2018-09-04 2021-07-14 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
CA3114208A1 (en) 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
KR102092838B1 (ko) 2018-10-02 2020-03-24 성균관대학교산학협력단 신규 퓨란계 폴리카보네이트 및 이의 제조 방법
US12162886B2 (en) 2018-10-03 2024-12-10 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
AU2019362788A1 (en) 2018-10-15 2021-04-15 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
PE20211693A1 (es) 2018-11-02 2021-09-01 Merck Sharp & Dohme 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
KR102151855B1 (ko) 2018-11-30 2020-09-03 롯데케미칼 주식회사 공액 디엔계 및 방향족 비닐계 공중합체의 제조 방법 및 이로부터 제조된 공액 디엔계 및 방향족 비닐계의 공중합체를 포함하는 타이어
US20220023270A1 (en) 2018-12-06 2022-01-27 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
WO2020123675A1 (en) 2018-12-11 2020-06-18 Duke University Compositions and methods for the treatment of cancer
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
JP7534306B2 (ja) 2019-01-22 2024-08-14 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 液晶ポリマーフィルムの製造方法
EP3917508A4 (en) 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
WO2020160225A1 (en) 2019-01-30 2020-08-06 Ohio State Innovation Foundation ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS
WO2020191227A1 (en) 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
WO2020221677A1 (en) 2019-04-30 2020-11-05 Merck Patent Gmbh Reactive mesogens
KR20220007681A (ko) 2019-05-10 2022-01-18 와커 헤미 아게 양이온성 게르마늄(ii) 화합물, 그의 제조 방법, 및 히드로실릴화에서의 촉매로서의 그의 용도
CA3136324A1 (en) 2019-05-14 2020-11-19 Philippe Nakache Acss2 inhibitors and methods of use thereof
US20220324880A1 (en) 2019-06-10 2022-10-13 Kymara Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2020254493A1 (en) 2019-06-21 2020-12-24 Bayer Aktiengesellschaft Thienylhydroxyisoxazolines and derivatives thereof
WO2021001739A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
MX2022004579A (es) 2019-10-17 2022-05-10 Enyo Pharma Derivados tiofeno para usarse en el tratamiento de inflamacion portal y fibrosis.
UY38979A (es) 2019-12-06 2021-07-30 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
WO2021125797A1 (ko) 2019-12-20 2021-06-24 주식회사 삼양홀딩스 올라파립의 용해도 및 생체이용율이 개선된 조성물
JP2023529099A (ja) 2020-05-28 2023-07-07 クルゲン（シャンハイ），インク． 修飾タンパク質およびタンパク質分解誘導薬
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
KR20230070300A (ko) 2020-09-24 2023-05-22 메르크 파텐트 게엠베하 중합성 액정 물질 및 중합된 액정 필름
WO2022070048A1 (en) 2020-09-29 2022-04-07 Cadila Healthcare Limited Novel amide derivatives
EP4232020A4 (en) 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
KR20240031300A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드

Also Published As

Publication number Publication date
WO2021113627A1 (en) 2021-06-10
CR20220316A (es) 2022-10-07
AR120680A1 (es) 2022-03-09
DK4069691T3 (da) 2024-10-28
EP4506001A2 (en) 2025-02-12
US20240391907A1 (en) 2024-11-28
PT4069691T (pt) 2024-12-18
CN114945566B (zh) 2024-11-12
CA3164134A1 (en) 2021-06-10
AU2020397059A1 (en) 2022-07-21
CO2022008969A2 (es) 2022-09-09
CL2022001489A1 (es) 2023-03-03
DOP2022000115A (es) 2022-09-30
FI4069691T3 (fi) 2024-11-13
US20230286961A1 (en) 2023-09-14
HRP20241695T1 (hr) 2025-02-14
EP4069691B1 (en) 2024-09-18
US11919887B2 (en) 2024-03-05
US20210198241A1 (en) 2021-07-01
JP2023504546A (ja) 2023-02-03
US11834441B2 (en) 2023-12-05
MX2022006865A (es) 2022-07-11
PH12022551379A1 (en) 2023-05-03
CN114945566A (zh) 2022-08-26
TW202128675A (zh) 2021-08-01
RS66307B1 (sr) 2025-01-31
JOP20220130A1 (ar) 2023-01-30
ECSP22052564A (es) 2022-08-31
PE20230300A1 (es) 2023-02-13
KR20220124176A (ko) 2022-09-13
SMT202400488T1 (it) 2025-01-14
LT4069691T (es) 2024-12-10
PL4069691T3 (pl) 2025-01-27
BR112022010924A2 (pt) 2022-09-06
EP4069691A1 (en) 2022-10-12
IL293592A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
UY38979A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
UY39800A (es) N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
CO2019013021A2 (es) Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY35288A (es) Piridonamidas como moduladores de canales de sodio
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
GT201400079A (es) Derivados de (4-fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
EA201992679A1 (ru) N-замещенные индольные производные
CO2021001216A2 (es) Derivados de espirocromano
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
BR112022010143A2 (pt) Inibidores de ahr e usos respectivos
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
CO2021010512A2 (es) Compuesto heterociclo pentacíclico
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
CL2012001818A1 (es) Compuestos derivados de 3-oxo-piridazina sustituida, antagonista b1, composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor y/o osteoartritis.